Redeye adjusts its forecasts following the FDA's issuance of another complete response letter (CRL) for Camurus. The problem was production issues, like in the previous CRL, and a minor labeling issue.
ANNONS
Redeye adjusts its forecasts following the FDA's issuance of another complete response letter (CRL) for Camurus. The problem was production issues, like in the previous CRL, and a minor labeling issue.
